Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in pediatric Ph+ leukemias
NCT00777036Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2009
- Primary completion
- Sep 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 18
01
Overview
A Phase 2 trial of dasatinib in chronic myeloid leukemia (CML), Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Bristol Myers Squibb. Started Mar 2009; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT00777036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777036.